U.S. Semiconductors Stock News

Appian Corporation recently presented at the WEST Conference 2026 at the San Diego Convention Center, sharing updates with defense and technology stakeholders about its low-code and automation capabilities. This appearance gives investors a fresh window into how Appian is positioning its platform for complex, regulated use cases that often demand robust workflow automation. Next, we’ll examine how Appian’s WEST Conference 2026 presentation might influence its investment narrative,...

Tesla (TSLA) is under pressure after January vehicle sales dropped 45% in China and 17% in the US, while it surrendered the top electric vehicle spot in Europe and increased spending on AI, robotics, and energy projects. See our latest analysis for Tesla. Against this backdrop of weaker vehicle demand and heavier spending on AI and robotics, Tesla’s share price has been choppy, with a 30 day share price return of a 4.59% decline, a 1 year total shareholder return of 17.31%, and a 3 year total...

IPG Photonics (NasdaqGS:IPGP) has introduced the CROSSBOW MINI High-Energy Laser system, a new scalable defense product aimed at countering drone threats. The company reports strong momentum in its medical business, supported by new product launches and a major customer win. Management has indicated that medical-related revenues are expected to double or triple in the next year. IPG Photonics, trading at about $153.91, has seen very strong recent share price performance, with the stock up...

Why Truist Financial is on investors’ radar Truist Financial (TFC) is back in focus after recent trading left the shares with a mixed return profile, including a small 1 day pullback but gains over the month and past 3 months. See our latest analysis for Truist Financial. While the 1 day share price return of a 0.33% decline to US$51.90 and the 7 day share price return of a 7.01% decline hint at some cooling after recent strength, the 30 day and 90 day share price returns of 3.82% and 18.17%...

In recent days, TJX Companies has drawn renewed attention as multiple Wall Street firms reiterated positive ratings, short interest eased, and investors looked ahead to the company’s upcoming fourth-quarter and full-year Fiscal 2026 earnings release and conference call held on February 25, 2026. Together with favorable earnings estimate revisions and a strong ranking from Zacks, these developments point to improving sentiment around TJX’s off-price retail model as it prepares to update the...

The board of Koppers Holdings Inc. ( NYSE:KOP ) has announced that the dividend on 23rd of March will be increased to...

Shareholders might have noticed that Mastercard Incorporated ( NYSE:MA ) filed its annual result this time last week...

Gold.com, Inc. ( NYSE:GOLD ) stock is about to trade ex-dividend in four days. The ex-dividend date is one business day...

As you might know, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) last week released its latest annual, and things did not...

To the annoyance of some shareholders, Sabre Corporation ( NASDAQ:SABR ) shares are down a considerable 26% in the last...

The Creative Global Technology Holdings Limited ( NASDAQ:CGTL ) share price has softened a substantial 39% over the...

Alliance Entertainment Holding Corporation ( NASDAQ:AENT ) shares have had a horrible month, losing 29% after a...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

1-800-FLOWERS.COM, Inc. ( NASDAQ:FLWS ) shares have retraced a considerable 25% in the last month, reversing a fair...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Elutia Inc. ( NASDAQ:ELUT ) shares have continued their recent momentum with a 28% gain in the last month alone. But...

The recent price decline of 15% in Cosmos Health Inc.'s ( NASDAQ:COSM ) stock may have disappointed insiders who bought...

To the annoyance of some shareholders, Cosmos Health Inc. ( NASDAQ:COSM ) shares are down a considerable 27% in the...

Investors may wish to note that the CEO, President & Director of Sagimet Biosciences Inc. , David Happel, recently...

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...

SLB (SLB) has secured multiple offshore drilling and well services contracts from Mubadala Energy for the Tangkulo deepwater natural gas project in Indonesia, highlighting the company’s offshore technologies and integrated model for investors. See our latest analysis for SLB. These new offshore awards arrive after a string of contract wins and technology partnerships. The share price reflects that momentum, with a 30 day share price return of 7.83% and a 90 day share price return of 40.75%,...

Phillips 66 recently reported fourth-quarter 2025 revenue of US$36,333 million and net income of US$2,906 million, and the board has approved a quarterly dividend of US$1.27 per share, payable on March 4, 2026, to shareholders of record on February 23, 2026. The combination of markedly higher quarterly earnings and a 5.8% dividend increase underscores how the company is using improved performance and portfolio changes to support shareholder payouts. We'll now examine how Phillips 66's...

Why Ridgepost Capital Is On Investors’ Radar Ridgepost Capital (RPC) recently rebranded from P10, Inc. This shift is putting fresh attention on how this multi asset class private market solutions provider is positioned across private equity, venture capital, impact investing, and private credit. See our latest analysis for Ridgepost Capital. At a latest share price of $8.70, Ridgepost Capital has seen a 2.35% 1 day share price return. Its 30 day share price return of 18.77% and 1 year total...

In February 2026, NovoCure announced that the U.S. FDA approved Optune Pax for adult patients with locally advanced pancreatic cancer, to be used alongside gemcitabine and nab-paclitaxel after the Phase 3 PANOVA-3 trial showed a statistically significant overall survival benefit without adding meaningful systemic side effects. This approval marks the first new treatment option for locally advanced pancreatic cancer in decades and further validates NovoCure’s Tumor Treating Fields technology...